BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: A comparison between DCOG/Erasmus MC and COG/St. Jude signatures

Haematologica

Volumn 100, Issue 9, 2015, Pages e354-e357

  Boer, Judith M ^a   Marchante, João R M ^a   Evans, William E ^b,c   Horstmann, Martin A ^d   Escherich, Gabriele ^d   Pieters, Rob ^a,e,f   Den Boer, Monique L ^a,e  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e DCOG Dutch Childhood Oncology Group   (Netherlands)

^f Department of Radiation Oncology   (Netherlands)

Author keywords

BCR ABL1 like ALL; CRLF2; Dic(9; 20); IAMP21; IKZF1; JAK2; Kinase; Prognosis; Translocation

Indexed keywords

JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EBF1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR IKZF1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; BCR ABL1 GENE; CHROMOSOME TRANSLOCATION; FUSION GENE; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE FUSION; GENE REARRANGEMENT; HIGH RISK POPULATION; HUMAN; LETTER; MUTATIONAL ANALYSIS; NUMERICAL CHROMOSOME ABERRATION; OVERLAPPING GENE; PRE B LYMPHOCYTE; PROGNOSIS; ADOLESCENT; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MALE; METABOLISM; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE;

EID: 84940923310     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.124941     Document Type: Letter

References (15)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-565
2. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125-134
3. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480
4. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153-166
5. Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children’s Oncology Group TARGET Project. Blood. 2013;121(3):485-488
6. Van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622-2629
7. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-5321
8. Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118(11):3080-3087
9. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24
10. Hicks C, Miele L, Koganti T, et al. Analysis of patterns of gene expression variation within and between ethnic populations in pediatric B-ALL. Cancer Inform. 2013;12:155-173
11. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015
12. Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with riskdirected therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32(27):3012-3020
13. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013;98(11):e146-148
14. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1- PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(25):e413-416
15. Harvey RC, Kang H, Roberts K, et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like (“Ph-like” or “BCR-ABL1-Like”) signature for therapeutic targeting and clinical intervention. Blood. 2013;122(21):826.